Immunocore Holdings plc (IMCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMCR POWR Grades
- Growth is the dimension where IMCR ranks best; there it ranks ahead of 88.52% of US stocks.
- IMCR's strongest trending metric is Growth; it's been moving down over the last 177 days.
- IMCR's current lowest rank is in the Momentum metric (where it is better than 4.75% of US stocks).
IMCR Stock Summary
- IMCR's went public 2.14 years ago, making it older than only 8.36% of listed US stocks we're tracking.
- With a price/sales ratio of 12.97, IMMUNOCORE HOLDINGS PLC has a higher such ratio than 92.37% of stocks in our set.
- As for revenue growth, note that IMCR's revenue has grown 383.22% over the past 12 months; that beats the revenue growth of 97.86% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to IMMUNOCORE HOLDINGS PLC, a group of peers worth examining would be TARS, DYAI, EYEN, SDGR, and ACVA.
- IMCR's SEC filings can be seen here. And to visit IMMUNOCORE HOLDINGS PLC's official web site, go to www.immunocore.com.
IMCR Stock Price Chart Interactive Chart >
IMCR Price/Volume Stats
| Current price | $47.52 | 52-week high | $69.06 |
| Prev. close | $47.86 | 52-week low | $25.01 |
| Day low | $46.73 | Volume | 299,300 |
| Day high | $50.62 | Avg. volume | 267,964 |
| 50-day MA | $56.21 | Dividend yield | N/A |
| 200-day MA | $52.21 | Market Cap | 2.09B |
Immunocore Holdings plc (IMCR) Company Bio
Immunocore Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops and commercializes a new generation of transformative medicines to address unmet needs in cancer, infection, and autoimmune diseases. Immunocore Holdings serves customers in the United Kingdom and the United States.
Latest IMCR News From Around the Web
Below are the latest news stories about IMMUNOCORE HOLDINGS PLC that investors may wish to consider to help them evaluate IMCR as an investment opportunity.
Top 10 Growth Stocks in BiotechIn this article, we will discuss the Top 10 Growth Stocks in Biotech. You can skip our industry overview and go directly to the Top 5 Growth Stocks in Biotech. The biotech industry encompasses a wide range of fields, including genetic engineering, biomanufacturing, bioinformatics, and synthetic biology. It has the potential to transform many aspects […] |
Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should KnowImmunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $46.71, moving -1.37% from the previous trading session. |
Immunocore Holdings PLC Sponsored ADR (IMCR) Gains But Lags Market: What You Should KnowImmunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $53.51, moving +1.61% from the previous trading session. |
Immunocore Holdings PLC Sponsored ADR (IMCR) Is a Trending Stock: Facts to Know Before Betting on ItRecently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store. |
Immunocore to present four posters at AACR Annual Meeting 2023Immunocore to present four posters at AACR Annual Meeting 2023 Updated three-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing early ctDNA reduction on tebentafusp-tebn associated with better overall survival in previously untreated metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 14 March 2023) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage bi |
IMCR Price Returns
| 1-mo | -13.36% |
| 3-mo | -16.73% |
| 6-mo | 1.24% |
| 1-year | 60.00% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -16.73% |
| 2022 | 66.68% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...